RUNX2 and breast cancer: At both 7 and 14 days, ES BC (set) exceeded AHP BC (set) and fresh groups in ALPL, RUNX2 and COL1A1 expression (p < 0.01), whereas some comparisons (e.g., RUNX2 at day 7) were not significant (p > 0.05).